# hifibio.com

> AI-optimized mirror of hifibio.com containing 210 pages totalling 110,445 words of clean markdown content, structured data, and semantic HTML. Original source: https://hifibio.com. Last updated: 2026-07-26T04:01:14.402Z.

Each page is available as HTML (with JSON-LD structured data) and Markdown (text-only, ideal for LLMs and RAG).

## Homepage

- [Home - HiFiBiO Therapeutics](/content/site-root.html) (215 words)

## Articles & Blog Posts

- [Single-Cell-Deep-Phenotyping-Nature-Biotechnology-Paper](/content/wp-content/uploads/2024/07/single-cell-deep-phenotyping-nature-biotechnology-paper-pdf.html) (2,198 words)
- [HFB200301-AACR-2020-Poster-1](/content/wp-content/uploads/2024/07/hfb200301-aacr-2020-poster-pdf.html) (1,230 words)
- [HFB200301-ASCO-2022-Poster](/content/wp-content/uploads/2024/07/hfb200301-asco-2022-poster-pdf.html) (791 words)
- [PowerPoint Presentation](/content/wp-content/uploads/2024/07/hfb301001-poster-asco-2024-final-pdf.html) (1,371 words)
- [Privacy Policy - HiFiBio Therapeutics](/content/privacy-policy/index.html): Last revised and effective as of: March 31, 2019 Welcome to our website! Please take a few minutes to carefully review these terms and conditions. By accessing and using this website you agree to follow and be bound by these terms and conditions. If you do not agree to follow and be bound by these […] (3,952 words)
- [Drug Intelligence Science (DIS�): Pioneering a high-resolution translational platform to enhance the probability of success for drug discovery and development](/content/wp-content/uploads/2024/07/dis-drug-intelligence-today-pdf.html) (2,230 words)
- [PowerPoint Presentation](/content/wp-content/uploads/2025/10/emunkitug-esmo-2025-poster_final-pdf.html) (1,317 words)
- [HFB9-2-AACR-2020-Poster](/content/wp-content/uploads/2024/07/hfb9-2-aacr-2020-poster-pdf.html) (222 words)
- [HFB301001-ESMO-2022-Poster](/content/wp-content/uploads/2024/07/hfb301001-esmo-2022-poster-pdf.html) (254 words)
- [HFB301001-AACR-2020-Poster](/content/wp-content/uploads/2024/07/hfb301001-aacr-2020-poster-pdf.html) (290 words)
- [Global or local: The future of biotech](/content/wp-content/uploads/2024/07/global-or-local-the-future-of-biotech-publication-pdf.html) (1,659 words)
- [DIS-AACR-2022-Poster](/content/wp-content/uploads/2024/07/dis-aacr-2022-poster-pdf.html) (1,109 words)
- [Gal-9-Nature-Scientific-Reports-Paper](/content/wp-content/uploads/2024/07/gal_9_nature_scientific_reports_paper-pdf.html) (10,670 words)
- [PowerPoint Presentation](/content/wp-content/uploads/2024/07/hfb101110-aacr-2022-poster-pdf.html) (1,276 words)
- [PowerPoint Presentation](/content/wp-content/uploads/2024/11/hfb200603-sitc-2024-final-1-pdf.html) (972 words)
- [High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics](/content/wp-content/uploads/2024/07/droplet-screening-nature-biotechnology-paper-pdf.html) (12,173 words)
- [PowerPoint Presentation](/content/wp-content/uploads/2025/05/hfb1002-cis-poster-2025-pdf.html) (1,060 words)
- [wp-content/uploads/2024/09/hfb200301-esmo-2024-poster-pdf.html](/content/wp-content/uploads/2024/09/hfb200301-esmo-2024-poster-pdf.html) (440 words)
- [Innovation-Drug-Discovery-Today-Paper](/content/wp-content/uploads/2024/07/innovation-drug-discovery-today-paper-pdf.html) (1,181 words)
- [PowerPoint Presentation](/content/wp-content/uploads/2025/06/focis-2025-poster_hfb302401_clean-pdf.html) (810 words)
- [PowerPoint Presentation](/content/wp-content/uploads/2025/06/focis-2025-poster_hfb200604_clean-pdf.html) (951 words)
- [CelliGO-Poster](/content/wp-content/uploads/2024/07/celligo-poster-pdf.html) (555 words)
- [PowerPoint Presentation](/content/wp-content/uploads/2024/11/hfb200301-sitc-2024-final-1-pdf.html) (1,307 words)
- [Page not found - HiFiBio Therapeutics](/content/pipeline/clinical-programs/hfb200301/index.html) (16 words)
- [Page not found - HiFiBio Therapeutics](/content/pipeline/clinical-programs/hfb301001/index.html) (14 words)
- [Page not found - HiFiBio Therapeutics](/content/pipeline/clinical-programs/hfb200604/index.html) (14 words)
- [PowerPoint Presentation](/content/wp-content/uploads/2025/10/hfb200603-esmo-2025-poster_final-pdf.html) (669 words)
- [Page not found - HiFiBio Therapeutics](/content/pipeline/clinical-programs/hfb200603/index.html) (14 words)
- [PowerPoint Presentation](/content/wp-content/uploads/2024/07/pkpd-model-aacr-2024-poster-final-pdf.html) (1,070 words)
- [PowerPoint Presentation](/content/wp-content/uploads/2025/06/focis-2025-poster_hfb202501_clean-pdf.html) (492 words)
- [High-throughput functional screening for next-generation cancer immunotherapy using droplet-based microfluidics](/content/wp-content/uploads/2024/07/droplet-screening-science-advances-paper-pdf.html) (10,201 words)
- [PowerPoint Presentation](/content/wp-content/uploads/2024/07/hfb200301-poster-asco-2024-final-version-pdf.html) (454 words)
- [Partnerships - HiFiBio Therapeutics](/content/partnering/partnerships/index.html): Collaborating to Transform Treatments We seek to collaborate with partners to advance our IO and I&I portfolio of targeted therapies Please send any inquiries by email to: bd@hifibio.com IO Programs Available for Partnership *As monotherapy or in combination with anti-PD-1, Tislelizumab, supply agreement with Novartis (462 words)
- [HFB200301-ASCO-2022-Poster](/content/wp-content/uploads/2024/07/hfb200603-aacr-2022-poster-pdf.html) (276 words)
- [Leadership - HiFiBio Therapeutics](/content/about/leadership/index.html) (717 words)
- [Scientific Founders - HiFiBio Therapeutics](/content/about/scientific-founders/index.html) (920 words)
- [Join Us - HiFiBio Therapeutics](/content/join-us/index.html): ,  (179 words)
- [DIS Platform - HiFiBiO Therapeutics](/content/science/index.html): Clinical Comprehensive data from imaging, sequencing, PK/PD analysis, and patient history is collected and analyzed to generate data-driven predictive biomarker hypotheses. This analysis generates insights for identifying predictive biomarkers to prospectively select patients for enhanced clinical response. Preclinical Extensive ex-vivo and computational analysis of patient samples is performed to gain insights into disease biology for […] (456 words)
- [Sample Page - HiFiBio Therapeutics](/content/sample-page/index.html): Entry Title Testing display of HTML elements – h1 tag This is 2nd level heading – h2 tag This is 3rd level heading – h3 tag This is 4th level heading – h4 tag This is 5th level heading This is 6th level heading This is a test paragraph. Basic block level elements TOGETHER WE… […] (615 words)
- [Company Overview - HiFiBio Therapeutics](/content/about/company-overview/index.html): Our History (262 words)
- [Pipeline Overview - HiFiBio Therapeutics](/content/pipeline/pipeline-overview/index.html): Our sustainable pipeline of immunomodulatory antibodies targets multiple cell types and key disease mechanisms (323 words)
- [Board of Directors - HiFiBio Therapeutics](/content/about/board-of-directors/index.html) (525 words)
- [HFB301001 - HiFiBio Therapeutics](/content/pipeline/programs/hfb301001/index.html): Targeting OX40 with a next generation agonist antibody for cancer immunotherapy OX40 is a TNF superfamily receptor expressed on activated CD4+ and CD8+ T cells and regulatory T cells. Several 1st generation OX40 agonists have shown modest clinical efficacy in cancer patients. Multiple factors, including OX40 target desensitization and competition with OX40 ligand, have been […] (305 words)
- [HFB200301 - HiFiBio Therapeutics](/content/pipeline/programs/hfb200301/index.html): Stimulating TNFR2 signaling in effector T and NK cells to promote anti-tumor immunity TNFR2 (tumor necrosis factor receptor 2) expression is highly regulated and restricted to immune cells, including CD4+, CD8+ T cells, NK and myeloid  cells. TNFR2 is primarily activated by its ligand, transmembrane TNFα, to drive immune cell activation, proliferation, and survival. Based […] (307 words)
- [HFB200603 - HiFiBio Therapeutics](/content/pipeline/programs/hfb200603/index.html): Targeting the BTLA/HVEM immunosuppressive axis to activate anti-tumor immunity BTLA (B and T lymphocyte attenuator) is a co-inhibitory immune checkpoint structurally related to PD-1 and CTLA-4. BTLA’s expression is restricted to immune cells, including B cells, CD4+ and CD8+ T cells, and dendritic cells. Upon interaction with its ligand HVEM, BTLA induces the recruitment of […] (259 words)
- [Scientific Advisory Board - HiFiBio Therapeutics](/content/about/scientific-advisory-board/index.html) (190 words)
- [HFB200604 - HiFiBio Therapeutics](/content/pipeline/programs/hfb200604/index.html): Stimulating BTLA to induce immune suppression in autoimmune and inflammatory diseases BTLA (B and T lymphocyte attenuator) is a co-inhibitory immune checkpoint structurally related to PD-1 and CTLA-4. BTLA’s expression is restricted to immune cells, including B cells, CD4+ and CD8+ T cells, and dendritic cells. Upon interaction with its ligand HVEM, BTLA induces the […] (196 words)
- [HFB3024 - HiFiBio Therapeutics](/content/pipeline/programs/hfb3024/index.html): HFB3024 is an anti-KLRG1 biparatopic antibody developed to deplete KLRG1+ cells via antibody dependent cellular cytotoxicity and phagocytosis. (165 words)
- [Open-Innovation Hub - HiFiBio Therapeutics](/content/partnering/open-innovation-hub/index.html): Welcoming open-innovation collaborations with high-potential biotechnology, biopharmaceutical, and life science start-ups Our Interest What We Offer (158 words)
- [Programs - HiFiBio Therapeutics](/content/pipeline/programs/index.html) (24 words)
- [Disclaimer - HiFiBio Therapeutics](/content/disclaimer/index.html): Disclaimer – Be aware of fraudulent recruitment scams HiFiBiO would like its prospective candidates to be aware of fraudulent recruitment scams that are currently taking place in the US and other countries. Please do not respond to those messages as these are scamming attempts. We have received reports about cases of candidates being invited by our […] (185 words)
- [2024-AACR-poster-scRNA-poster-V1.5](/content/wp-content/uploads/2024/07/dis-aacr-2024-poster-pdf.html) (1,154 words)
- [wp-content/uploads/2024/09/hfb200603-esmo-2024-poster-pdf.html](/content/wp-content/uploads/2024/09/hfb200603-esmo-2024-poster-pdf.html) (515 words)
- [Alexandre Grassin - HiFiBio Therapeutics](/content/alexandre-grassin-2/index.html): Alexandre Grassin is Senior Vice President, Head of Finance at HiFiBiO Therapeutics. He is a seasoned biotech finance executive with over 25 years of international experience across the U.S. and Europe, spanning both private and public companies. Alex has supported multiple equity and debt financings and played a central role in bringing companies to the […] (157 words, Feb 10, 2026)
- [Timothy Miller, MSc - HiFiBio Therapeutics](/content/timothy-miller-msc/index.html): Tim Miller is Head of Business Development at HiFiBiO Therapeutics, where he leads global partnering strategy to advance the company’s biotherapeutic pipeline. He brings more than a decade of experience across business development, alliance management, and strategic contracting within the life sciences and biotechnology sectors. Prior to HiFiBiO, Tim served as Director of Business Development […] (160 words, Feb 10, 2026)
- [Yun-Yueh Lu, PhD - HiFiBio Therapeutics](/content/yun-yueh-lu-phd/index.html): Yun-Yueh Lu is the Head of Research, Head of China Operations at HiFiBiO Therapeutics. She is a biologist with 10 years of biopharma industry experience. She currently oversees all aspects of preclinical research activities, along with managing general operational responsibilities in China. Prior to joining HiFiBiO Therapeutics, she was part of the team at Sanofi, where […] (109 words, Feb 10, 2026)
- [Melissa Harney - HiFiBio Therapeutics](/content/melissa-harney/index.html): Melissa Harney is the Head of Clinical Operations & Regulatory Affairs at HiFiBiO Therapeutics, where she leads global clinical execution and regulatory strategy across the company’s Immunology & Inflammation and Immuno-Oncology programs. She brings over 20 years of experience in clinical development, regulatory oversight, and global trial operations within the biotech and pharmaceutical sectors. Prior […] (150 words, Feb 10, 2026)
- [HiFiBiO Therapeutics Announces the Appointment of Leading I&I Experts to its Scientific Advisory Board - HiFiBio Therapeutics](/content/hifibio-therapeutics-announces-the-appointment-of-leading-ii-experts-to-its-scientific-advisory-board.html): CAMBRIDGE, MA – October 30, 2025 – HiFiBiO Therapeutics, a clinical stage immune modulation biotechnology company, today announces the addition of three distinguished leaders in the field of inflammation and immunology to its Scientific Advisory Board (SAB): Peter Taylor, PhD, Marco Londei, MD, and Deepak Rao, MD, PhD. The new members join an esteemed group […] (328 words, Oct 30, 2025)
- [Evaluation of HVEM and PD-L1 Expression Profile in Tumors as Potential Predictive Biomarkers forHFB200603, a BTLA antagonist, as Monotherapy and in Combination with Tislelizumab - HiFiBio Therapeutics](/content/evaluation-of-hvem-and-pd-l1-expression-profile-in-tumors-as-potential-predictive-biomarkers-forhfb200603-a-btla-antagonist-as-monotherapy-and-in-combination-with-tislelizumab.html) (25 words, Oct 20, 2025)
- [Potential Predictive Biomarkers of Clinical Benefit from Emunkitug (HFB200301) in Combination withTislelizumab: Integrated Analysis of Tumor, Peripheral Blood, and Patient Treatment History - HiFiBio Therapeutics](/content/potential-predictive-biomarkers-of-clinical-benefit-from-emunkitug-hfb200301-in-combination-withtislelizumab-integrated-analysis-of-tumor-peripheral-blood-and-patient-treatment-history.html) (23 words, Oct 20, 2025)
- [HiFiBiO Therapeutics to Present Updated Phase 1 Clinical Data of Two Immuno-Oncology Programs at the 2025 Annual Meeting of the European Society for Medical Oncology (ESMO)  - HiFiBio Therapeutics](/content/hifibio-therapeutics-to-present-updated-phase-1-clinical-data-of-two-immuno-oncology-programs-at-the-2025-annual-meeting-of-the-european-society-for-medical-oncology-esmo.html): CAMBRIDGE, MA – September 25, 2025 – HiFiBiO Therapeutics, a clinical stage immune modulation biotechnology company, announced its participation in the 2025 Annual Meeting of the European Society for Medical Oncology (ESMO), taking place October 17-21 in Berlin, Germany.  The company will present exciting Phase 1 clinical data on two immuno-oncology programs: the first-in-class anti-TNFR2 […] (321 words, Sep 25, 2025)
- [Application of HiFiBiO Drug Intelligence Science (DIS®) translational platform to guide the clinical development of HFB200604, a Phase I BTLA agonist monoclonal antibody - HiFiBio Therapeutics](/content/application-of-hifibio-drug-intelligence-science-dis-translational-platform-to-guide-the-clinical-development-of-hfb200604-a-phase-i-btla-agonist-monoclonal-antibody.html) (23 words, Jun 26, 2025)
- [HFB202501, a Novel Anti-PD-1 Antibody with Enhanced Effector Functions for Precision Depletion of Pathogenic T Cells in Autoimmune Diseases - HiFiBio Therapeutics](/content/hfb202501-a-novel-anti-pd-1-antibody-with-enhanced-effector-functions-for-precision-depletion-of-pathogenic-t-cells-in-autoimmune-diseases.html) (19 words, Jun 25, 2025)
- [A Novel Biparatopic KLRG1 Antibody Selectively Depletes Effector Memory CD8+ T Cells for Autoimmune Disease Treatment - HiFiBio Therapeutics](/content/a-novel-biparatopic-klrg1-antibody-selectively-depletes-effector-memory-cd8-t-cells-for-autoimmune-disease-treatment.html) (16 words, Jun 24, 2025)
- [HiFiBiO Therapeutics to Present Preclinical Data of Three Leading I&I Programs at the 2025 Annual Meeting of the Federation of Clinical Immunology Societies - HiFiBio Therapeutics](/content/hifibio-therapeutics-to-present-preclinical-data-of-three-leading-ii-programs-at-the-2025-annual-meeting-of-the-federation-of-clinical-immunology-societies.html): CAMBRIDGE, MA – June 18, 2025 – HiFiBiO Therapeutics, a clinical stage immune modulation biotechnology company, announced its participation in the 2025 Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS), taking place June 24-27 in Boston, MA. The company will present exciting preclinical data on three novel leading immunology programs: a bi-paratopic KLRG1 […] (327 words, Jun 18, 2025)
- [CXCR5 as a Therapeutic Target in Autoimmune Diseases: Insights from Sjögren’s Disease - HiFiBio Therapeutics](/content/cxcr5-as-a-therapeutic-target-in-autoimmune-diseases-insights-from-sjogrens-disease.html) (12 words, May 2, 2025)
- [HiFiBiO Therapeutics to Present Preclinical Data for A Novel Immunology Antibody at the 2025 Annual Meeting of the Clinical Immunology Society  - HiFiBio Therapeutics](/content/hifibio-therapeutics-to-present-preclinical-data-for-a-novel-immunology-antibody-at-the-2025-annual-meeting-of-the-clinical-immunology-society.html): CAMBRIDGE, MA – April 29, 2025 – HiFiBiO Therapeutics, a clinical stage immune modulation biotechnology company today announced its participation in the 2025 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 1-4 in Philadelphia, PA.  The company will present compelling preclinical data on HFB100204, a novel CXCR5 depleting antibody for the treatment […] (497 words, Apr 29, 2025)
- [HiFiBiO CEO Liang Schweizer sits down with NYSE Floor Talk on how HiFiBiO is using AI to transform drug development - HiFiBio Therapeutics](/content/hifibio-ceo-liang-schweizer-sits-down-with-nyse-floor-talk-on-how-hifibio-is-using-ai-to-transform-drug-development.html) (20 words, Nov 27, 2024)
- [Utilizing Drug Intelligence Science (DIS®) for tumor type selection and molecular characterization of HFB200603, a best-in-class B and T Lymphocyte Attenuator (BTLA) monoclonal antagonist - HiFiBio Therapeutics](/content/utilizing-drug-intelligence-science-dis-for-tumor-type-selection-and-molecular-characterization-of-hfb200603-a-best-in-class-b-and-t-lymphocyte-attenuator-btla-monoclonal-antagonist.html) (24 words, Nov 8, 2024)
- [Predictive and generative AI to guide the clinical development of HFB200301, a first-in-class TNFR2 agonist: Drug Intelligence Science (DIS®) - HiFiBio Therapeutics](/content/predictive-and-generative-ai-to-guide-the-clinical-development-of-hfb200301-a-first-in-class-tnfr2-agonist-drug-intelligence-science-dis.html) (19 words, Nov 8, 2024)
- [HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200604, a Best-in-Class BTLA Agonist Antibody for the Treatment of Inflammatory and Immunology Diseases  - HiFiBio Therapeutics](/content/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200604-a-best-in-class-btla-agonist-antibody-for-the-treatment-of-inflammatory-and-immunology-diseases.html): CAMBRIDGE, MA.– November 4, 2024 – HiFiBiO Therapeutics, a clinical-stage biotechnology company focused on immune modulation, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for HFB200604. HFB200604 is a best-in-class BTLA agonist monoclonal antibody, developed using HiFiBiO’s proprietary Drug Intelligence Science (DIS®) platform. The therapy […] (380 words, Nov 4, 2024)
- [Drug Intelligence Science (DIS®): Pioneering a high-resolution translational platform to enhance the probability of success for drug discovery and development - HiFiBio Therapeutics](/content/drug-intelligence-science-dis-pioneering-a-high-resolution-translational-platform-to-enhance-the-probability-of-success-for-drug-discovery-and-development-2.html) (20 words, Oct 23, 2024)
- [HiFiBiO Therapeutics to Showcase DIS® Enabled Translational Insights from Ongoing Phase 1 Clinical Trials for Two Novel Immuno-Oncology Antibodies at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - HiFiBio Therapeutics](/content/hifibio-therapeutics-to-showcase-dis-enabled-translational-insights-from-ongoing-phase-1-clinical-trials-for-two-novel-immuno-oncology-antibodies-at-the-2024-annual-meeting-of-the-society-for-im.html): CAMBRIDGE, MA – October 7, 2024 – HiFiBiO Therapeutics, a clinical stage immune modulation biotechnology company today announced its participation in the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 6-10 in Houston, Texas. The company will present a pioneering clinical development strategy, showcasing the predictive power of its […] (379 words, Oct 7, 2024)
- [HiFiBiO Therapeutics to Present Phase 1 Clinical Trial Data for Two Novel Immuno-Oncology Antibodies at the 2024 Annual Congress of the European Society for Medical Oncology - HiFiBio Therapeutics](/content/hifibio-therapeutics-to-present-phase-1-clinical-trial-data-for-two-novel-immuno-oncology-antibodies-at-the-2024-annual-congress-of-the-european-society-for-medical-oncology.html): CAMBRIDGE, MA – August 22, 2024 – HiFiBiO Therapeutics, a clinical stage immune modulation biotechnology company today announced its participation in the 2024 Annual Congress of the European Society for Medical Oncology (ESMO), taking place September 13-17 in Barcelona, Spain. The company will present compelling Phase 1 trial data on two novel monoclonal antibodies: the first-in-class TNFR2 […] (482 words, Sep 14, 2024)
- [Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody, in monotherapy and in combination with the anti-PD-1 tislelizumab in patients with advanced solid tumors - HiFiBio Therapeutics](/content/model-informed-dose-optimization-of-hfb200301-a-tnfr2-agonist-monoclonal-antibody-in-monotherapy-and-in-combination-with-the-anti-pd-1-tislelizumab-in-patients-with-advanced-solid-tumors.html) (25 words, Sep 14, 2024)
- [Phase I Dose Escalation Study of HFB200603, a Best-in-Class BTLA Antagonist Monoclonal Antibody in Monotherapy and in Combination with the Anti-PD-1 mAb Tislelizumab in Adult Patients with Advanced Solid Tumors - HiFiBio Therapeutics](/content/phase-i-dose-escalation-study-of-hfb200603-a-best-in-class-btla-antagonist-monoclonal-antibody-in-monotherapy-and-incombination-with-the-anti-pd-1-mab-tislelizumab-in-adult-patients-with-advanced-sol.html) (30 words, Sep 14, 2024)
- [Lynn Yang, MBA - HiFiBio Therapeutics](/content/lynn-yang/index.html): Lynn Yang is a Partner at HongShan, focusing on the healthcare sector, where she has led investments in numerous renowned healthcare enterprises. Prior to joining HongShan in 2015, she worked at Legend Capital healthcare team. Previously, Lynn Yang served as a Business Development Manager and Product Manager at major multinational companies such as Johnson & […] (93 words, Jul 9, 2024)
- [Cheryl Cui, PhD - HiFiBio Therapeutics](/content/cheryl-cui-ph-d/index.html): Cheryle Cui is a Partner at Nest.Bio Ventures and CEO of Bota. She was a former Venture Partner at VentureHealth, a Silicon Valley-based healthcare fund, where she coordinated portfolio companies’ growth strategy in the Asia Pacific. Cheryl previously co-founded a mobile health company that facilitates the care of Alzheimer’s patients, which was successfully acquired in […] (117 words, Jul 9, 2024)
- [Andrew Griffiths, PhD - HiFiBio Therapeutics](/content/andrew-griffiths-phd/index.html): Andrew Griffiths is a Professor of Biochemistry at École Supérieure de Chimie Industrielles de Paris (ESPCI) in Paris. Prof Griffiths is formerly the holder of a Chaire d’Excellence from the Ministère pour la Recherche, France, at the Institut de Science et d’Ingénierie Supramoléculaires (ISIS) in Strasbourg. After receiving a BSc in Biochemistry (First Class) from […] (194 words, Jul 2, 2024)
- [Jérôme Bibette, PhD - HiFiBio Therapeutics](/content/jerome-bibette-phd/index.html): Jérôme Bibette is the Professor of soft matter physics at École Supérieure de Chimie Industrielles de Paris (ESPCI). Jérôme is the co-director of the Michelin Advanced Research Initiative at ESPCI and is best known for his work in the areas of emulsions and superparamagnetic colloids, microfluidics, rheology, fluid mechanics, colloid chemistry, biophysics, complex fluids, soft […] (114 words, Jul 2, 2024)
- [Robert Nicol, PhD - HiFiBio Therapeutics](/content/robert-nicol-phd/index.html): Rob Nicol is a Venture Partner at RA Capital Management. Previously at the Broad Institute under Rob’s guidance, the Technology Labs served as an advanced R&D group within the institute integrating capabilities in molecular biology, bio-engineering, synthetic biology, microfluidics, bio-informatics, and industrial process design to meet the needs of the Broad community. Rob is also […] (186 words, Jul 2, 2024)
- [David Weitz, PhD - HiFiBio Therapeutics](/content/david-weitz-phd/index.html): Dave Weitz is the Mallinckrodt Professor of Physics & Applied Physics and professor of Systems Biology at Harvard University. Dave is the co-director of the BASF Advanced Research Initiative at Harvard, co-director of the Harvard Kavli Institute for BioNano Science & Technology, and director of the Harvard Materials Research Science & Engineering Center. He is […] (190 words, Jul 2, 2024)
- [Bradley Bernstein, MD, PhD - HiFiBio Therapeutics](/content/bradley-bernstein-md-phd/index.html): Bradley Bernstein is a Director of Gene Regulation Observatory at the Broad Institute of MIT and Harvard. and a Professor at the Dana-Farber Cancer Institute. Brad co-directs the Broad Institute’s Epigenomics Program and oversees data production centers for the ENCODE project and the NIH Common Fund for Epigenomics. His research focuses on epigenetics—changes in gene […] (223 words, Jul 2, 2024)
- [Sebastian Amigorena, PhD - HiFiBio Therapeutics](/content/sebastian-amigorena-phd/index.html) (22 words, Jul 2, 2024)
- [Peter Ho, MD, PhD - HiFiBio Therapeutics](/content/peter-ho-md-phd/index.html) (27 words, Jul 2, 2024)
- [Michael Croft, PhD - HiFiBio Therapeutics](/content/michael-croft-phd/index.html): Director of Scientific Affairs, Professor for the Center of Autoimmunity and Inflammation at La Jolla Institute for Immunology (40 words, Jul 2, 2024)
- [Leslie Kean, MD, PhD - HiFiBio Therapeutics](/content/leslie-kean-md-phd/index.html) (23 words, Jul 2, 2024)
- [Peter Taylor, MA, PhD, FRCP, FRCPE - HiFiBio Therapeutics](/content/peter-taylor-ma-phd-frcp-frcpe/index.html) (15 words, Jul 2, 2024)
- [Marco Londei, MD - HiFiBio Therapeutics](/content/marco-londei-md/index.html) (14 words, Jul 2, 2024)
- [Deepak Rao, MD, PhD - HiFiBio Therapeutics](/content/deepak-rao-md-phd/index.html) (25 words, Jul 2, 2024)
- [EY Announces Liang Schweizer of HiFiBiO Therapeutics as an Entrepreneur Of The Year® 2024 New England Award Winner - HiFiBio Therapeutics](/content/ey-announces-liang-schweizer-of-hifibio-therapeutics-as-an-entrepreneur-of-the-year-2024-new-england-award-winner.html): Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives CAMBRIDGE, Mass. – June 13, 2024 – Ernst & Young LLP (EY US) today announced that Liang Schweizer, PhD, CEO, Chairperson, and Founder of HiFiBiO Therapeutics was named an Entrepreneur Of The Year® 2024 New England Award winner. Entrepreneur Of The Year is […] (1,030 words, Jun 13, 2024)
- [MJ Kim - HiFiBio Therapeutics](/content/mj-kim/index.html): MJ Kim is a Vice President at Mirae Asset Capital. He has invested in Septerna (NASDAQ: SEPN), 858 Therapeutics, and Precede Biosciences, and serves on the board of Navigantis. He focuses on investing in pioneering companies across drug discovery, diagnostics, and medical devices. Before joining Mirae Asset, MJ was a Senior Scientist at SCAI Therapeutics […] (95 words, Jun 13, 2024)
- [Fred Dom, MSc - HiFiBio Therapeutics](/content/fred-dom-2/index.html): Fred Dom is one of the original founders and Chief Executive Officer of HiFiBiO Therapeutics. He is a serial entrepreneur with expertise in private capital investment and biotech formation in the Netherlands, France, and US. Fred holds board positions in Calyxia (France), Kapsera (France) and Oncode Accelerator (Dutch public-private initiative with €325 million funding from National […] (134 words, Jun 13, 2024)
- [Roshan Kumar, PhD - HiFiBio Therapeutics](/content/roshan-kumar-ph-d/index.html): Roshan Kumar is the Head of Translational Medicine at HiFiBiO Therapeutics. He is a scientist with over 20 years of experience in the study of complex biological systems, with a focus on human immunology and immune-mediated disease. Roshan has been with HiFiBiO for more than a decade, where he has helped develop and apply the […] (176 words, Jun 5, 2024)
- [Jinping Gan, PhD - HiFiBio Therapeutics](/content/jinping-gan-ph-d/index.html): Jinping is the Senior Vice President, Head of Research and Development at HiFiBiO Therapeutics. Jinping has more than 25 years of experience in drug discovery and development. Prior to HiFiBiO, Jinping was at Bristol-Myers Squibb working on preclinical optimization and nonclinical characterization of diverse NCEs in oncology, immunology, CV, and fibrotic diseases, contributing to the […] (90 words, Jun 4, 2024)
- [Phase I Dose Escalation Trial of the First-in-Class TNFR2 Agonist Monoclonal Antibody, HFB200301, in Monotherapy and in Combination with Tislelizumab, an Anti-PD-1 Monoclonal Antibody, in adult Patients with Advanced Solid Tumors - HiFiBio Therapeutics](/content/phase-i-dose-escalation-trial-of-the-first-in-class-tnfr2-agonist-monoclonal-antibody-hfb200301-in-monotherapy-and-in-combination-with-tislelizumab-an-anti-pd-1-monoclonal-antibody-in-adult-patien.html) (31 words, Jun 1, 2024)
- [A Phase I Monotherapy Dose Escalation Study of HFB301001, a Novel Next Generation OX40 agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors - HiFiBio Therapeutics](/content/a-phase-i-monotherapy-dose-escalation-study-of-hfb301001-a-novel-next-generation-ox40-agonist-monoclonal-antibody-in-adult-patients-with-advanced-solid-tumors.html) (24 words, Jun 1, 2024)
- [HiFiBiO Therapeutics to Present Phase 1 Clinical Trial Data for Two Novel Immuno-Oncology Agonists at the 2024 Annual Meeting of the American Society of Clinical Oncology - HiFiBio Therapeutics](/content/hifibio-therapeutics-to-present-phase-1-clinical-trial-data-for-two-novel-immuno-oncology-agonists-at-the-2024-annual-meeting-of-the-american-society-of-clinical-oncology.html): CAMBRIDGE, MA – May 24, 2024 – HiFiBiO Therapeutics, an innovative clinical stage biotechnology company committed to improving patient lives with single cell precision, today announced its participation in the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO), set for May 31-June 4, 2024, in Chicago, IL.   The company will present Phase […] (601 words, May 24, 2024)
- [Zixuan Pang, PhD - HiFiBio Therapeutics](/content/zixuan-pang-ph-d/index.html): Zixuan is the Vice President at IDG Capital. He focuses on early-stage biotech investments, new modality, and disruptive biotechnologies. Before becoming the Vice President, Zixuan served as Associate at IDG Capital in Beijing, dealing sourcing, research, and led a few investments in the biotech sector.  Zixuan received his Ph.D. in Philosophy, Neuroscience, Dermatology, and Biochemistry […] (83 words, May 9, 2024)
- [EY Announces Liang Schweizer of HiFiBiO Therapeutics as an Entrepreneur Of The Year® 2024 New England Award Finalist - HiFiBio Therapeutics](/content/ey-announces-liang-schweizer-of-hifibio-therapeutics-as-an-entrepreneur-of-the-year-2024-new-england-award-finalist.html): Entrepreneur Of The Year celebrates ambitious entrepreneurs who are shaping the future  CAMBRIDGE, Mass. – Apr 17, 2024 –– Ernst & Young LLP (EY US) today announced that Liang Schweizer, PhD, CEO, Chairperson, and Founder of HiFiBiO Therapeutics was named an Entrepreneur Of The Year® 2024 New England Award finalist. Now in its 38th year, […] (936 words, Apr 17, 2024)
- [HiFiBiO Therapeutics Receives Grant to Research Long COVID and ME/CFS in Collaboration with UMass Chan Medical School - HiFiBio Therapeutics](/content/hifibio-therapeutics-receives-grant-to-research-long-covid-and-me-cfs-in-collaboration-with-umass-chan-medical-school.html): CAMBRIDGE, Mass. – Apr 16, 2024 – HiFiBiO Therapeutics, a clinical stage biotech company focusing on improving patient lives with single cell precision, today announced a new grant awarded by the Patient-Led Research Fund, a project of Patient-Led Research Collaborative and funded by Balvi. This grant is dedicated to a research initiative in collaboration with […] (653 words, Apr 16, 2024)
- [Optimization of T cell Co-Stimulatory Agonists: A Semi-Mechanistic PKPD Model Integrating Drug Properties and Tumor-Immune Interactions - HiFiBio Therapeutics](/content/optimization-of-t-cell-co-stimulatory-agonists-a-semi-mechanistic-pkpd-model-integrating-drug-properties-and-tumor-immune-interactions.html) (16 words, Apr 10, 2024)
- [Integrating Public Single-Cell Transcriptomics and Patient Profiles to Guide Clinical Development - HiFiBio Therapeutics](/content/integrating-public-single-cell-transcriptomics-and-patient-profiles-to-guide-clinical-development.html) (11 words, Apr 9, 2024)
- [HiFiBiO Therapeutics Presents Two Posters at the 2024 American Association for Cancer Research Annual Meeting - HiFiBio Therapeutics](/content/hifibio-therapeutics-presents-two-posters-at-the-2024-american-association-for-cancer-research-annual-meeting.html): CAMBRIDGE, MA – April 7, 2024 – HiFiBiO Therapeutics, a leading clinical stage global biotechnology company committed to advancing patient outcomes through single-cell precision, presented two posters at the AACR 2024 meeting held on April 5-10, 2024, in San Diego, CA. “One of the major challenges cancer immunotherapies face is the difficulties in selecting patients […] (552 words, Apr 8, 2024)
- [HiFiBiO Therapeutics to Present at 2024 American Association for Cancer Research Annual Meeting - HiFiBio Therapeutics](/content/hifibio-therapeutics-to-present-at-2024-american-association-for-cancer-research-annual-meeting.html): CAMBRIDGE, MA – March 21, 2024 – HiFiBiO Therapeutics, a leading clinical stage global biotechnology company committed to advancing patient outcomes through single-cell precision, announced today its participation in the AACR 2024 meeting, scheduled to take place April 5-10, 2024, in San Diego, CA.     On Tuesday, April 9th, Dr. Jack Russella-Pollard will present an […] (408 words, Mar 21, 2024)
- [Helmuth Van Es, PhD - HiFiBio Therapeutics](/content/helmuth-van-es-phd/index.html): Helmuth van Es is a seasoned biotech entrepreneur and strategic advisor with more than 30 years of experience spanning drug discovery, company building, and corporate strategy. He has co-founded multiple international biotechnology companies, including Galapagos, Citryll, Antabio, Audion Therapeutics, and Effecta Pharma, advancing programs from discovery through clinical development, including earlycontributions to an approved therapy. […] (213 words, Feb 14, 2024)
- [Fred Dom, MSc - HiFiBio Therapeutics](/content/fred-dom/index.html): Fred Dom is one of the original founders and Chief Executive Officer of HiFiBiO Therapeutics. He is a serial entrepreneur with expertise in private capital investment and biotech formation in the Netherlands, France, and US. Fred holds board positions in Calyxia (France), Kapsera (France) and Oncode Accelerator (Dutch public-private initiative with €325 million funding from National […] (134 words, Feb 13, 2024)
- [CEO Liang Schweizer Sits with Nasdaq to Share HiFiBiO Therapeutics’ Mission to Unlock the Curative Powers of the Immune System - HiFiBio Therapeutics](/content/ceo-liang-schweizer-sits-with-nasdaq-to-share-hifibio-therapeutics-mission-to-unlock-the-curative-powers-of-the-immune-system.html): CAMBRIDGE, MA., – January 7, 2024 – HiFiBiO Therapeutics Founder, Chairperson, and CEO Liang Schweizer sits down with Nasdaq Live from MarketSite to discuss how HiFiBiO Therapeutics is revolutionizing the development of immunotherapies by gaining an unprecedented understanding of immune dysregulation at the single cell level. HiFiBiO’s unique high-resolution translational DIS® platform enhances the probability […] (230 words, Jan 7, 2024)
- [HiFiBiO Therapeutics Collaborates with Institut Gustave Roussy and France 2030 Initiative to Pioneer Personalized Immunotherapies - HiFiBio Therapeutics](/content/hifibio-therapeutics-collaborates-with-institut-gustave-roussy-and-france-2030-initiative-to-pioneer-personalized-immunotherapies.html): Paris, France, and Cambridge, MA, December 11, 2023 – HiFiBiO Therapeutics, a leading clinical stage global biotech company dedicated to advancing patient outcomes through single-cell precision, proudly announces its strategic collaboration with clinical institutions and life science companies in the formation of a groundbreaking consortium under the France 2030 Initiative. This visionary project, named REMISSION […] (395 words, Dec 11, 2023)
- [HiFiBiO Therapeutics Drug Intelligence Science DIS® Platform Wins “AI Innovation of the Year” in 2023 BioTech Breakthrough Awards - HiFiBio Therapeutics](/content/hifibio-therapeutics-drug-intelligence-science-dis-platform-wins-ai-innovation-of-the-year-in-2023-biotech-breakthrough-awards.html): Cambridge, MA, November 8, 2023 – HiFiBiO Therapeutics, a clinical stage global biotech company with the goal of improving patient lives with single-cell precision, today announced that BioTech Breakthrough has named its proprietary translational platform, Drug Intelligence Science (DIS®) as the BioTech AI Innovation of the Year. The annual awards program features the best and […] (416 words, Nov 8, 2023)
- [Drug Intelligence Science (DIS®) – A Cutting-Edge Translational Platform Pioneered by HiFiBiO Therapeutics – Featured in Drug Discovery Today - HiFiBio Therapeutics](/content/drug-intelligence-science-dis-a-cutting-edge-translational-platform-by-hifibio-therapeutics-featured-in-drug-discovery-today.html): Drug Intelligence Science (DIS®) – Pioneering a High-Resolution Translational Platform to Enhance Probability of Success for Drug Discovery and Development   CAMBRIDGE, MA., – October 23, 2023 – HiFiBiO Therapeutics Founder, Chairperson, and CEO Liang Schweizer presents, in the peer-reviewed journal Drug Discovery Today, the company’s proprietary translational platform Drug Intelligence Science (DIS®), highlighting its potential […] (497 words, Oct 23, 2023)
- [Drug Intelligence Science (DIS®): Pioneering a High-Resolution Translational Platform to Enhance the Probability of Success for Drug Discovery and Development - HiFiBio Therapeutics](/content/drug-intelligence-science-dis-pioneering-a-high-resolution-translational-platform-to-enhance-the-probability-of-success-for-drug-discovery-and-development.html) (20 words, Oct 17, 2023)
- [HiFiBiO Therapeutics Receives Approval from Chinese NMPA for IND Application for HFB200301, an Innovative Anti-Tumor Monoclonal Antibody - HiFiBio Therapeutics](/content/hifibio-therapeutics-receives-approval-from-chinese-nmpa-for-ind-application-for-hfb200301-an-innovative-anti-tumor-monoclonal-antibody.html): CAMBRIDGE, MA – October 9, 2023 – HiFiBiO Therapeutics, a clinical stage global biotech company focusing on improving patient lives with single cell precision, announced today that the Chinese National Medical Products Administration (NMPA) has approved the company’s Investigational New Drug (IND) application for HFB200301, a pioneering, first-in-class anti-TNFR2 agonistic monoclonal antibody. HFB200301 is currently […] (480 words, Oct 10, 2023)
- [Fierce Biotech Names HiFiBiO Therapeutics a “Fierce 15” Biotech Company of 2023 - HiFiBio Therapeutics](/content/fierce-biotech-names-hifibio-therapeutics-a-fierce-15-biotech-company-of-2023.html): Cambridge, MA., – August 28, 2023 – HiFiBiO Therapeutics, a clinical stage global biotech company focusing on improving patient lives with single cell precision, today announced that Fierce Biotech has named it as one of 2023’s “Fierce 15” biotechnology companies. The annual special report features the most innovative and promising early-stage biotechnology companies in the […] (472 words, Aug 28, 2023)
- [Robert Andtbacka, MD, CM joins HiFiBiO Therapeutics as Chief Medical Officer - HiFiBio Therapeutics](/content/robert-andtbacka-md-cm-joins-hifibio-therapeutics-as-chief-medical-officer.html): CAMBRIDGE, Mass. – June 28th, 2023 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, today announced the appointment of Robert Andtbacka, MD, CM, as the Chief Medical Officer to oversee the company’s clinical activities, reporting to HiFiBiO’s Founder, Chairperson, and CEO, Dr. Liang Schweizer. “I’m very excited to have such an experienced and well-recognized clinical […] (498 words, Jun 28, 2023)
- [HiFiBiO Therapeutics Announces First Patient First Visit for the Evaluation of HFB200301 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid Tumors - HiFiBio Therapeutics](/content/hifibio-therapeutics-announces-first-patient-first-visit-for-the-evaluation-of-hfb200301-in-combination-with-tislelizumab-in-patients-with-dis-selected-advanced-solid-tumors.html): CAMBRIDGE, MA – June 23, 2023 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today that the first patient has been dosed with HiFiBiO’s HFB200301, a first-in-class agonistic anti-TNFR2 monoclonal antibody, in combination with tislelizumab, an investigational anti-PD-1 immune checkpoint inhibitor, for the treatment of advanced solid tumor indications preselected by HiFiBiO’s proprietary Drug […] (392 words, Jun 23, 2023)
- [HiFiBiO Therapeutics CEO Liang Schweizer Shares Her Professional Journey and the Company’s Pioneering DIS® Approach on the Biotech2050 Podcast - HiFiBio Therapeutics](/content/hifibio-therapeutics-ceo-liang-schweizer-shares-her-professional-journey-and-the-companys-pioneering-dis-approach-on-the-biotech2050-podcast.html): CAMBRIDGE, MA., – June 14, 2023 – HiFiBiO Therapeutics founder, Chairperson and CEO Liang Schweizer speaks with Rahul Chaturvedi on the Biotech2050 Podcast about her journey from scientist to first-time CEO and how HiFiBiO is improving the success rate of immunotherapies by leveraging unprecedented single-cell level insights into patient heterogeneity. HiFiBiO aims at changing the […] (314 words, Jun 14, 2023)
- [Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study - HiFiBio Therapeutics](/content/safety-tolerability-pharmacokinetics-and-immunogenicity-of-an-anti-sars-cov-2-monoclonal-antibody-hfb30132a-after-single-dose-intravenous-administration-in-healthy-chinese-subjects-a-phase-1-rand.html) (27 words, May 23, 2023)
- [HiFiBio Therapeutics -](/content/hifibio-therapeutics-announces-oral-presentation-at-2023-american-association-for-cancer-research-aacr-annual-meeting.html): HiFiBiO Therapeutics Announces Oral Presentation at 2023 American Association for Cancer Research (AACR) Annual Meeting (341 words, Apr 7, 2023)
- [HiFiBio Therapeutics -](/content/going-global-insights-on-the-advantages-of-biotech-globalization-published-in-drug-discovery-today-from-hifibio-therapeutics.html): Going Global: Insights on the Advantages of Biotech Globalization Published in Drug Discovery Today from HiFiBiO Therapeutics (346 words, Mar 6, 2023)
- [HiFiBio Therapeutics -](/content/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603.html): HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603 (385 words, Jan 6, 2023)
- [HiFiBio Therapeutics -](/content/hifibio-therapeutics-ceo-liang-schweizer-interviewed-by-life-science-success-podcast.html): HiFiBiO Therapeutics CEO Liang Schweizer Interviewed by Life Science Success Podcast (138 words, Jan 5, 2023)
- [HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200603 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid Tumors - HiFiBio Therapeutics](/content/hifibio-therapeutics-announces-clinical-trial-supply-agreement-to-evaluate-hfb200603-in-combination-with-tislelizumab-in-patients-with-dis-selected-advanced-solid-tumors-2.html): CAMBRIDGE, MA – November 18, 2022 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today a second clinical trial supply agreement with Novartis to evaluate HiFiBiO’s HFB200603, a novel anti-BLTA monoclonal antibody in combination with tislelizumab, Novartis anti-PD-1 immune checkpoint inhibitor, for the treatment of advanced solid tumor indications preselected by HiFiBiO’s proprietary Drug […] (343 words, Nov 18, 2022)
- [Phase I Study of HFB301001, a Novel OX40 Agonist Monoclonal Antibody, in Patients with Solid Tumors Selected via Drug Intelligence Science (DIS™) - HiFiBio Therapeutics](/content/phase-i-study-of-hfb301001-a-novel-ox40-agonist-monoclonal-antibody-in-patients-with-solid-tumors-selected-via-drug-intelligence-science-dis.html) (22 words, Sep 12, 2022)
- [HiFiBiO Therapeutics to Present Trial in Progress Poster for HFB301001 at 2022 ESMO Congress - HiFiBio Therapeutics](/content/hifibio-therapeutics-to-present-trial-in-progress-poster-for-hfb301001-at-2022-esmo-congress.html): CAMBRIDGE, MA – September 5th , 2022 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today that clinical trial investigator, Anthony B. El-Khoueiry, MD, Associate Director for Clinical Research and Phase I Program Director at the University of Southern California, Norris Comprehensive Cancer Center, and Associate Professor of Clinical Medicine at the Keck School […] (479 words, Sep 5, 2022)
- [HiFiBio Therapeutics -](/content/hifibio-therapeutics-announces-clinical-trial-supply-agreement-to-evaluate-hfb200301-in-combination-with-tislelizumab-in-patients-with-dis-selected-advanced-solid-tumors.html): HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200301 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid Tumors (499 words, Aug 15, 2022)
- [Phase I Study of HFB200301, a First-in-Class TNFR2 Agonist Monoclonal Antibody in Patients with Solid Tumors Selected via Drug Intelligent Science (DIS™) - HiFiBio Therapeutics](/content/phase-i-study-of-hfb200301-a-first-in-class-tnfr2-agonist-monoclonal-antibody-in-patients-with-solid-tumors-selected-via-drug-intelligent-science-dis.html) (22 words, Apr 27, 2022)
- [HiFiBio Therapeutics -](/content/hifibio-therapeutics-to-present-trial-in-progress-poster-for-hfb200301-at-the-2022-american-society-of-clinical-oncology-asco-annual-meeting.html): HiFiBiO Therapeutics to Present Trial in Progress Poster for HFB200301 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (461 words, Apr 27, 2022)
- [Targeting Regulatory T Cells with HFB101110, a Novel Anti-Human CCR8 Antibody for the Treatment of Solid Tumors - HiFiBio Therapeutics](/content/targeting-regulatory-t-cells-with-hfb101110-a-novel-anti-human-ccr8-antibody-for-the-treatment-of-solid-tumors.html) (17 words, Apr 18, 2022)
- [HiFiBio Therapeutics -](/content/hfb200603-a-novel-anti-btla-monoclonal-antibody-that-provides-therapeutic-potential-for-immune-escape-and-synergizes-with-anti-pd-1-treatment-2.html): HFB200603, a novel anti-BTLA monoclonal antibody that provides therapeutic potential for immune escape and synergizes with anti-PD-1 treatment (20 words, Apr 18, 2022)
- [HiFiBio Therapeutics - News](/content/targeting-regulatory-t-cells-with-hfb101110-a-novel-anti-human-ccr8-antibody-for-the-treatment-of-solid-tumors-2.html): Targeting regulatory T cells with HFB101110, a novel anti-human CCR8 antibody for the treatment of solid tumors (32 words, Apr 18, 2022)
- [HiFiBio Therapeutics -](/content/discovery-of-predictive-biomarkers-of-response-to-t-cell-targeting-biologics-using-ex-vivo-single-cell-profiling-coupled-with-tcr-clonotype-characterization-2.html): Discovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterization (34 words, Apr 18, 2022)
- [HFB200603, a Novel Anti-BTLA Monoclonal Antibody that Provides Therapeutic Potential for Immune Escape and Synergizes with Anti-PD-1 Treatment - HiFiBio Therapeutics](/content/hfb200603-a-novel-anti-btla-monoclonal-antibody-that-provides-therapeutic-potential-for-immune-escape-and-synergizes-with-anti-pd-1-treatment.html) (18 words, Apr 13, 2022)
- [Discovery of Predictive Biomarkers of Response to T Cell-Targeting Biologics Using Ex Vivo Single-Cell Profiling Coupled with TCR Clonotype Characterization - HiFiBio Therapeutics](/content/discovery-of-predictive-biomarkers-of-response-to-t-cell-targeting-biologics-using-ex-vivo-single-cell-profiling-coupled-with-tcr-clonotype-characterization.html) (20 words, Apr 8, 2022)
- [HiFiBio Therapeutics - News](/content/hifibio-therapeutics-announces-three-presentations-at-2022-american-association-for-cancer-research-aacr-annual-meeting.html): HiFiBiO Therapeutics Announces Three Presentations at 2022 American Association for Cancer Research (AACR) Annual Meeting (424 words, Apr 4, 2022)
- [HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB301001 - HiFiBio Therapeutics](/content/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb301001.html): HFB301001 is a potential best-in-class OX40 agonist antibody for the treatment of DIS® defined solid tumors CAMBRIDGE, MA., HONG KONG, HANGZHOU, SHANGHAI, and PARIS – Jan 10, 2022 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application […] (347 words, Jan 10, 2022)
- [FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program - HiFiBio Therapeutics](/content/fibrogen-exercises-exclusive-license-option-for-hifibios-ccr8-program.html): Exclusive license option to anti-CCR8 monoclonal antibody program further strengthens FibroGen’s preclinical development pipeline HiFiBiO to receive $35 million option exercise payment, potential milestones and royalties SAN FRANCISCO, CA and CAMBRIDGE, MA, December 20, 2021 (GLOBE NEWSWIRE) – FibroGen, Inc. (Nasdaq: FGEN), a leading biopharmaceutical company discovering, developing, and commercializing first-in-class therapeutics, and HiFiBiO Therapeutics, […] (821 words, Dec 20, 2021)
- [HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200301 - HiFiBio Therapeutics](/content/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200301.html): HFB200301 is a First-In-Class TNFR2 Agonist Antibody for the treatment of DIS® Defined Solid Tumors CAMBRIDGE, MA., HONG KONG, HANGZHOU, SHANGHAI, and PARIS – November 1, 2021 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for […] (427 words, Nov 1, 2021)
- [Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study - HiFiBio Therapeutics](/content/defining-variant-resistant-epitopes-targeted-by-sars-cov-2-antibodies-a-global-consortium-study.html) (11 words, Oct 22, 2021)
- [HiFiBiO Therapeutics Contributes to CoVIC-Led Science Publication on SARS-CoV-2 Spike Antibodies Effective Against Variants of Concern - HiFiBio Therapeutics](/content/hifibio-therapeutics-contributes-to-covic-led-analysis-on-the-identification-of-distinct-epitope-communities-among-sars-cov-2-spike-antibodies-efficacious-against-variants-of-concern.html): CAMBRIDGE, MA., HONG KONG, HANGZHOU, SHANGHAI, PARIS – September 23, 2021 – HiFiBiO Therapeutics, a multinational biotechnology company with unique expertise in immune modulation and single-cell science, today announced a publication in Science in collaboration with the Coronavirus Immunotherapy Consortium (CoVIC), a global, academic-industry, non-profit research alliance that was established to accelerate discovery, optimization, and delivery of […] (384 words, Sep 23, 2021)
- [FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease - HiFiBio Therapeutics](/content/fibrogen-and-hifibio-announce-transformative-partnership-to-advance-next-generation-therapies-for-patients-with-cancer-and-autoimmune-disease.html): FibroGen Exclusively Licenses HiFiBiO’s Galectin-9 Program, and Obtains an Exclusive Option to their CXCR5 and CCR8 Programs Transformative Transaction for FibroGen’s Early-stage Pipeline HiFiBiO to Receive $25 Million Upfront, and Up to a Total of $1.1B in Additional Milestone Payments Across All Three Programs, Plus Royalties SAN FRANCISCO, CA and CAMBRIDGE, MA, June 17, 2021 […] (939 words, Jun 17, 2021)
- [HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline with Two Lead Immuno-Oncology Programs and Validate its DIS® Approach in the Clinic - HiFiBio Therapeutics](/content/hifibio-therapeutics-closes-75-million-series-d-financing-to-accelerate-pipeline-with-two-lead-immuno-oncology-programs-and-validate-its-dis-approach-in-the-clinic.html): Latest funding led by Mirae Asset Financial Group and joined by B Capital Group, Sherpa, and other new investors together with existing investors such as IDG and Sequoia Capital China CAMBRIDGE, Mass., HONG KONG, HANGZHOU, SHANGHAI, and PARIS, – June 14, 2021 – HiFiBiO Therapeutics, a multinational biotechnology company with unique expertise in immune modulation […] (1,073 words, Jun 14, 2021)
- [High-Throughput Functional Screening for Next-Generation Cancer Immunotherapy Using Droplet-Based Microfluidics - HiFiBio Therapeutics](/content/high-throughput-functional-screening-for-next-generation-cancer-immunotherapy-using-droplet-based-microfluidics.html) (10 words, Jun 11, 2021)
- [HiFiBiO Therapeutics Announces Publication in Science Advances of its High-Throughput Functional Screening for Next-Generation Cancer Immunotherapy - HiFiBio Therapeutics](/content/hifibio-therapeutics-announces-publication-in-science-advances-of-its-high-throughput-functional-screening-for-next-generation-cancer-immunotherapy.html): HiFiBio Therapeutics announced a publication in Science Advances with its collaborators at Nankai University, ShanghaiTech University, and Jiao Tong University about the development of a high-throughput droplet-based approach to identify novel antibodies with functional readouts beyond simple binding. (472 words, Jun 11, 2021)
- [A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes - HiFiBio Therapeutics](/content/a-sars-cov-2-neutralizing-antibody-with-extensive-spike-binding-coverage-and-modified-for-optimal-therapeutic-outcomes.html) (15 words, May 11, 2021)
- [HiFiBiO Therapeutics Announces Publication in Nature Communications on its SARS-CoV-2 Neutralizing Monoclonal Antibody - HiFiBio Therapeutics](/content/hifibio-therapeutics-announces-publication-in-nature-communications-on-its-sars-cov-2-neutralizing-monoclonal-antibody.html): HFB30132A possesses differentiated properties providing strong potential for COVID-19 treatment and prevention HONG KONG – May 11, 2021 – HiFiBiO Therapeutics, a multinational biotechnology company with unique expertise in immune modulation and single-cell science, today announced a publication in Nature Communications with its collaborators at Xinhua Hospital and Nankai University on the preclinical data for its SARS-CoV-2 […] (855 words, May 11, 2021)
- [HFB9-2, a Novel Galectin 9 Neutralizing Antibody for the Treatment of AML and Other Cancers - HiFiBio Therapeutics](/content/hfb9-2-a-novel-galectin-9-neutralizing-antibody-for-the-treatment-of-aml-and-other-cancers.html) (15 words, Apr 13, 2021)
- [Discovery and Characterization of a Novel Anti-Human CXCR5 Antibody for the Treatment of B Cell Lymphomas - HiFiBio Therapeutics](/content/discovery-and-characterization-of-a-novel-anti-human-cxcr5-antibody-for-the-treatment-of-b-cell-lymphomas.html) (16 words, Apr 12, 2021)
- [Clinical Approach and Biomarker Strategy for HFB301001, a Novel OX40 Agonistic Antibody - HiFiBio Therapeutics](/content/clinical-approach-and-biomarker-strategy-for-hfb301001-a-novel-ox40-agonistic-antibody.html) (12 words, Apr 12, 2021)
- [Mechanism of Action and Biomarker Strategy for HFB200301, an Anti-TNFR2 Agonist Antibody for the Treatment of Cancer - HiFiBio Therapeutics](/content/mechanism-of-action-and-biomarker-strategy-for-hfb200301-an-anti-tnfr2-agonist-antibody-for-the-treatment-of-cancer.html) (17 words, Apr 12, 2021)
- [Clinical approach and biomarker strategy for HFB301001, a novel OX40 agonistic antibody - HiFiBio Therapeutics](/content/clinical-approach-and-biomarker-strategy-for-hfb301001-a-novel-ox40-agonistic-antibody-2.html): Presenters: Ross Fulton, Jinping Gan, Yun-Yueh Lu, Julianna Crivello, Zachery Duda, Zhiyuan Wang, Rebecca Silver, Alexandra Staskus, Charina Ortega, Sami Ellouze, Carine George, Sophie Foulon, Wenhua Xu, Xing Cai, Joyce Pi, Dean Lee, Monika Manne, Ruina Jin, Yuan Wang, Hongkai Zhang, Nicola Beltraminelli, Francisco Adrian, Robert Petit, Liang Schweizer, Andreas Raue HFB301001 is being developed […] (90 words, Apr 12, 2021)
- [HFB9-2, a novel Galectin 9 neutralizing antibody for the treatment of AML and other cancers - HiFiBio Therapeutics](/content/hfb9-2-a-novel-galectin-9-neutralizing-antibody-for-the-treatment-of-aml-and-other-cancers-2.html): Presenters: Germain Margall, Muriel David, Julie Prigent, Dean Lee, Wenhua Xu, Joyce Pi, Xing Cai, Tengfei Wang, Ouyang Li, He Zhou, Andreas Raue, Nicola Beltraminelli, Mingjie Chen, Jia Wu, Mingfang Feng, Angelo Paci, Julia Delahousse, Véronique Saada, Stéphane de Botton, Pierre Busson, Stephanie Beq, Francisco Adrian, Liang Schweizer, Yun-Yueh Lu HFB2009 program focuses on developing […] (94 words, Apr 12, 2021)
- [Mechanism of Action and Biomarker Strategy for HFB200301, an Anti-TNFR2 Agonist Antibody for the Treatment of Cancer - HiFiBio Therapeutics](/content/mechanism-of-action-and-biomarker-strategy-for-hfb200301-an-anti-tnfr2-agonist-antibody-for-the-treatment-of-cancer-2.html): Presenters: Shuo Wei, Ross Fulton, Yun-Yueh Lu, Qian Zhang, He Zhou, Andreas Raue, Mingjie Chen, Wenhua Xu, Xing Cai, Juliana Crivello, Zachary Duda, Zhiyuan Wang, Rebecca Silver, Alexandra Staskus, Charina Ortega, Sami Ellouze, Carine George, Sophie Foulon, Dean Lee, Monika Manne, Nicola Beltraminelli, Jinping Gan, Francisco Adrian, Liang Schweizer, Jennifer Watkins-Yoon HFB200301 is an anti-TNFR2 […] (90 words, Apr 12, 2021)
- [Discovery and characterization of a novel anti-human CXCR5 antibody for the treatment of B cell lymphomas - HiFiBio Therapeutics](/content/discovery-and-characterization-of-a-novel-anti-human-cxcr5-antibody-for-the-treatment-of-b-cell-lymphomas-2.html): Presenters: Ayrin Kök, Germain Margallducos, Stephanie Beq, Clarisse Monchecourt, Hombline Poullain, Muriel David, Sami Ellouze, Carine George, Mingjie Chen, Yun-Yueh Lu, Juying Li, Qian Zhang, Jean Wang, Adam Woolfe, Louise Gody, Francisco Adrian, Liang Schweizer, Nicola Beltraminelli HFB1002 program focuses on the development of monoclonal antibodies against human CXCR5 as a novel treatment for B-cell […] (78 words, Apr 12, 2021)
- [HiFiBiO Therapeutics to Present Progress on Four Novel Immunotherapy Programs at AACR 2021 - HiFiBio Therapeutics](/content/hifibio-therapeutics-to-present-progress-on-four-novel-immunotherapy-programs-at-aacr-2021.html): HiFiBiO Therapeutics to present four e-posters detailing recent advancements on the following programs: HFB2003, HFB3010, HFB1002, and HFB2009. CAMBRIDGE, Mass. – April 6, 2021 – Scientists at HiFiBiO Therapeutics will share with the scientific community preclinical data for novel monoclonal antibodies for clinical development as new cancer immunotherapeutic options. Two of these programs, HFB3010 and […] (686 words, Apr 6, 2021)
- [HiFiBiO and Gustave Roussy Researchers Demonstrate the Contribution of Galectin-9 (Gal-9) in Tumor Immune Escape - HiFiBio Therapeutics](/content/hifibio-and-gustave-roussy-researchers-demonstrate-the-contribution-of-galectin-9-gal-9-in-tumor-immune-escape.html): Research published in Nature Scientific Reports demonstrates the ablation of Gal-9 produced by malignant cells is linked with reduction in tumor growth in a MB49 murine model. Paris, France – March 19, 2021 – HiFiBiO Therapeutics in collaboration with researchers at Gustave Roussy have uncovered galectin-9’s contribution to tumor immune escape in a MB49 murine […] (538 words, Mar 19, 2021)
- [HiFiBiO Therapeutics CEO Liang Schweizer Interviewed by Lioness Magazine - HiFiBio Therapeutics](/content/hifibio-therapeutics-ceo-liang-schweizer-interviewed-by-lioness-magazine.html): Dr. Schweizer discusses her journey as a scientist, executive, and founder of HiFiBiO as she leads the advancement of a pipeline of antibody drugs in cancer, autoimmune diseases, and COVID-19. CAMBRIDGE, Mass. – March 11, 2021 – HiFiBiO Therapeutics CEO Liang Schweizer interviewed with Lioness Magazine to share how the company is combining its deep-rooted […] (172 words, Mar 11, 2021)
- [HiFiBiO Therapeutics CEO Liang Schweizer Interviewed by PharmaBoardRoom and Genialis Podcast - HiFiBio Therapeutics](/content/hifibio-therapeutics-ceo-liang-schweizer-interviewed-by-pharmaboardroom-and-genialis-podcast.html): Dr. Schweizer discusses HiFiBiO’s unique single-cell technology platform, shares her industry experience, and offers advice for other biotech leaders. CAMBRIDGE, Mass. – March 3, 2021 – HiFiBiO Therapeutics CEO Liang Schweizer took an opportunity to speak with PharmaBoardRoom and Genialis Podcast to share HiFiBiO’s unique single-cell technology platform and open innovation approach, her capital markets […] (176 words, Mar 8, 2021)
- [Serial Transplantation Unmasks Galectin‐9 Contribution to Tumor Immune Escape in the MB49 Murine Model - HiFiBio Therapeutics](/content/serial-transplantation-unmasks-galectin-e2-80-909-contribution-to-tumor-immune-escape-in-the-mb49-murine-model.html) (14 words, Mar 4, 2021)
- [HiFiBiO Therapeutics CEO Liang Schweizer Named one of the World’s Top Female Founders - HiFiBio Therapeutics](/content/hifibio-therapeutics-ceo-liang-schweizer-named-one-of-the-worlds-top-female-founders.html): Dr. Schweizer continues to be recognized for long-term vision, open-innovation strategy, commitment to diversity, and ability to secure more than $100 million in financing CAMBRIDGE, Mass. – October 27, 2020 – HiFiBiO Therapeutics, a multinational biotherapeutics company with unique expertise in immune modulation and single-cell science, today announced its President and CEO Liang Schweizer, PhD, […] (552 words, Oct 27, 2020)
- [HiFiBiO Therapeutics Completes First Cohort of a Phase I Study of its SARS-CoV-2 Neutralizing Antibody for the Treatment and Prevention of COVID-19 - HiFiBio Therapeutics](/content/hifibio-therapeutics-completes-first-cohort-of-a-phase-i-study-of-its-sars-cov-2-neutralizing-antibody-for-the-treatment-and-prevention-of-covid-19.html): HFB30132A study design is published in ClinicalTrial.gov and primary data readout is expected in late 2020 CAMBRIDGE, Mass. – October 26, 2020 – HiFiBiO Therapeutics, a multinational biotherapeutics company with unique expertise in immune modulation and single-cell science, today announced the successful completion of the first cohort of the Phase I study (NCT04590430) of HFB30132A, […] (631 words, Oct 26, 2020)
- [HiFiBiO Therapeutics CEO Liang Schweizer Receives 2020 Extraordinary Women Advancing Healthcare Award - HiFiBio Therapeutics](/content/hifibio-therapeutics-ceo-liang-schweizer-receives-2020-extraordinary-women-advancing-healthcare-award.html): The Commonwealth Institute Recognizes Women Leaders in Massachusetts Demonstrating Impact, Inspiration, and Innovation across Healthcare Industry CAMBRIDGE, Mass., – September 24, 2020 – HiFiBiO Therapeutics today announced its CEO, Liang Schweizer, PhD, has been recognized with an Extraordinary Women Advancing Healthcare Award (EWAH) by The Commonwealth Institute (TCI), the leading nonprofit organization devoted to advancing […] (603 words, Sep 24, 2020)
- [HiFiBiO Therapeutics Presents Novel Approach to Patient Stratification Demonstrating DIS™ Single-Cell Platform at 2020 AACR Tumor Heterogeneity Conference - HiFiBio Therapeutics](/content/hifibio-therapeutics-presents-novel-approach-to-patient-stratification-demonstrating-dis-single-cell-platform-at-2020-aacr-tumor-heterogeneity-conference.html) (18 words, Sep 17, 2020)
- [HiFiBiO Therapeutics Presents Novel Approach to Patient Stratification Demonstrating DIS® Single-Cell Platform at 2020 AACR Tumor Heterogeneity Conference - HiFiBio Therapeutics](/content/hifibio-therapeutics-presents-novel-approach-to-patient-stratification-demonstrating-dis-single-cell-platform-at-2020-aacr-tumor-heterogeneity-conference-2.html): CAMBRIDGE, Mass., – September 17, 2020 – HiFiBiO Therapeutics is presenting a novel approach for patient stratification demonstrating its proprietary Drug Intelligent Science (DIS®) single-cell platform at the American Association for Cancer Research (AACR) Tumor Heterogeneity Virtual Special Conference taking place today. The company is a pioneer of novel antibody drug discovery and development, leveraging […] (321 words, Sep 17, 2020)
- [KITE AND HIFIBIO THERAPEUTICS PARTNER TO DISCOVER NOVEL TARGETS AND ANTIBODIES AGAINST ACUTE MYELOID LEUKEMIA - HiFiBio Therapeutics](/content/kite-and-hifibio-therapeutics-partner-to-discover-novel-targets-and-antibodies-against-acute-myeloid-leukemia.html): Research Collaboration will Leverage HiFiBiO’s Proprietary Single-Cell Platform to Identify Novel Targets to Support Kite’s Development of Cell Therapies in AML Santa Monica, Calif. and Cambridge, Mass., September 3, 2020 – Kite, a Gilead Company (Nasdaq: GILD), and HiFiBiO Therapeutics announced the companies have entered into a two-year research collaboration and license agreement in acute […] (658 words, Sep 3, 2020)
- [HiFiBiO Therapeutics Submits IND Application for Fully Human SARS-CoV-2 Neutralizing Antibody for the Treatment of COVID-19 Patients - HiFiBio Therapeutics](/content/hifibio-therapeutics-submits-ind-application-for-fully-human-sars-cov-2-neutralizing-antibody-for-the-treatment-of-covid-19-patients.html): Company leverages its unprecedented antibody drug discovery and development engine empowered by proprietary single-cell profiling platform to identify, engineer, and develop a novel therapy against SARS-CoV-2 ready for clinical studies in less than six months CAMBRIDGE, Mass. – August 26, 2020 – HiFiBiO Therapeutics, a multinational biotherapeutics company focused on the development of novel antibodies […] (559 words, Aug 26, 2020)
- [HiFiBiO Therapeutics Collaborates with Coronavirus Immunotherapy Consortium in the Fight Against COVID-19 - HiFiBio Therapeutics](/content/hifibio-therapeutics-collaborates-with-coronavirus-immunotherapy-consortium-in-the-fight-against-covid-19.html): Company leverages its unprecedented antibody drug discovery and development engine empowered by proprietary single-cell profiling technology to identify, engineer, and evaluate multiple neutralizing antibodies against SARS-CoV-2 CAMBRIDGE, Mass. – August 17, 2020 – HiFiBiO Therapeutics, a multinational biotherapeutics company focused on the development of novel antibodies for immunomodulation, today announced a collaboration with the Coronavirus […] (562 words, Aug 17, 2020)
- [HFB9-2, a Novel Galectin-9 Neutralizing Antibody to Reverse Immune Suppression in the Tumor Microenvironment - HiFiBio Therapeutics](/content/hfb9-2-a-novel-galectin-9-neutralizing-antibody-to-reverse-immune-suppression-in-the-tumor-microenvironment.html) (14 words, Jul 3, 2020)
- [HFB301001, a Novel OX40 agonistic Antibody with a Unique Pharmacological Profile and Innovative Biomarker Strategy - HiFiBio Therapeutics](/content/hfb301001-a-novel-ox40-agonistic-antibody-with-a-unique-pharmacological-profile-and-innovative-biomarker-strategy.html) (15 words, Jul 3, 2020)
- [Discovery and Characterization of Novel TNFR2 Antibodies to Modulate T Cell Activities in Immunosuppressive Environment - HiFiBio Therapeutics](/content/discovery-and-characterization-of-novel-tnfr2-antibodies-to-modulate-t-cell-activities-in-immunosuppressive-environment.html) (15 words, Jul 3, 2020)
- [HFB9-2, a novel Galectin-9 neutralizing antibody to reverse immune suppression in the tumor microenvironment - HiFiBio Therapeutics](/content/hfb9-2-a-novel-galectin-9-neutralizing-antibody-to-reverse-immune-suppression-in-the-tumor-microenvironment-2.html): Presenters: Roshan Kumar, PhD, Senior Director, Head of Discovery Biology and US External Innovation and Yun-Yueh Lu, PhD, Project Leader, Principal Scientist, Disease Biology HFB2009 program focuses on developing anti-Gal-9 neutralizing antibodies as a potential first-in-class treatment for AML and solid tumors, both as a single agent and a combination therapy. More information about these […] (189 words, Jul 3, 2020)
- [Discovery and characterization of novel TNFR2 antibodies to modulate T cell activities in immunosuppressive environment - HiFiBio Therapeutics](/content/discovery-and-characterization-of-novel-tnfr2-antibodies-to-modulate-t-cell-activities-in-immunosuppressive-environment-2.html): Presenters: Francisco Adrian, PhD, Senior Vice President, Head of Research and Shuo Wei, PhD, Project Leader, Principal Scientist, Disease Biology HFB200301 is an anti-TNFR2 monoclonal antibody being developed as a potential first-in-class therapeutic for the treatment of biomarker-selected patients with advanced cancer. More information about these and other programs in the HiFiBiO Therapeutics pipeline is […] (169 words, Jul 3, 2020)
- [HFB301001, a novel OX40 agonistic antibody with a unique pharmacological profile and innovative biomarker strategy - HiFiBio Therapeutics](/content/hfb301001-a-novel-ox40-agonistic-antibody-with-a-unique-pharmacological-profile-and-innovative-biomarker-strategy-2.html): Presenters: Andreas Raue, PhD, Project Leader, Senior Director, Head of Drug Intelligent Science (DIS®) at HiFiBiO Therapeutics and Robert Petit, PhD, Senior Scientific Advisor HFB301001 is being developed as a potential novel treatment option for cancer coupled with a patient stratification biomarker in solid tumor indications. More information about these and other programs in the […] (184 words, Jul 3, 2020)
- [HiFiBiO Therapeutics Presents Three Novel Immuno-Oncology Programs at 2020 AACR Virtual Annual Meeting II - HiFiBio Therapeutics](/content/hifibio-therapeutics-presents-three-novel-immuno-oncology-programs-at-2020-aacr-virtual-annual-meeting-ii.html): Audio recordings of scientific presentations explicate preclinical data for three novel antibody drug candidates in the HiFiBiO Therapeutics pipeline CAMBRIDGE, Mass., PARIS, SHANGHAI, and HONG KONG– June 22, 2020 – HiFiBiO Therapeutics is presenting its three lead pipeline programs at the American Association for Cancer Research (AACR) Virtual Annual Meeting II taking place today. The […] (500 words, Jun 22, 2020)
- [HiFiBiO Therapeutics Unveils Several Novel Antibodies Showing Promise to Be Precision Immunotherapies for Cancer Patients - HiFiBio Therapeutics](/content/hifibio-therapeutics-unveils-several-novel-antibodies-showing-promise-to-be-precision-immunotherapies-for-cancer-patients.html): HiFiBiO Therapeutics will take a pioneering approach to clinical development of its pipeline of antibody candidates by using patient stratification biomarkers identified by the company’s proprietary Drug Intelligent Science (DIS®) CAMBRIDGE, Mass., SHANGHAI, and PARIS – May 15, 2020 – Scientists at HiFiBiO Therapeutics have generated preclinical data packages for novel monoclonal antibodies that demonstrate […] (971 words, May 15, 2020)
- [Droplet Microfluidic Screening and Sequencing Can Vastly Expand the Universe of New Antibody Therapeutics - HiFiBio Therapeutics](/content/high-throughput-single-cell-activity-based-screening-and-sequencing-of-antibodies-using-droplet-microfluidics-2-2.html): Research published in Nature Biotechnology shows how single-cell microfluidic technology can rapidly reveal previously hidden immune responses, with potential applications in multiple disease areas including COVID-19 CAMBRIDGE, Mass., SHANGHAI, and PARIS – March 30, 2020 – Scientists at HiFiBiO Therapeutics, in a multi-year collaboration with researchers at ESPCI Paris – PSL and other organizations, have […] (568 words, Mar 30, 2020)
- [High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics - HiFiBio Therapeutics](/content/high-throughput-single-cell-activity-based-screening-and-sequencing-of-antibodies-using-droplet-microfluidics-2.html): Mining the antibody repertoire of plasma cells and plasmablasts could enable the discovery of useful antibodies for therapeutic or research purposes1. (11 words, Mar 30, 2020)
- [High-Throughput Single-Cell Activity-Based Screening and Sequencing of Antibodies Using Droplet Microfluidics - HiFiBio Therapeutics](/content/high-throughput-single-cell-activity-based-screening-and-sequencing-of-antibodies-using-droplet-microfluidics.html) (11 words, Mar 20, 2020)
- [Biotechs Build on Single-cell Analytics for Drug R&D, as Human Cell Atlas is Mapped - HiFiBio Therapeutics](/content/biotechs-build-on-single-cell-analytics-for-drug-research-and-development-as-human-cell-atlas-is-mapped.html): By Stacy Lawrence, Dec. 10, 2019 Efforts to rationalize drug development with more precise understanding of genetics and biology and the interrelation between the two haven’t been particularly fruitful. Serendipity largely retains its hold on R&D, even as genomics, transcriptomics, proteomics and metabolomics have all worked to better characterize the layers of information that are […] (1,796 words, Jan 11, 2020)
- [HiFiBiO Therapeutics Establishes World-Class Scientific Advisory Board - HiFiBio Therapeutics](/content/hifibio-therapeutics-establishes-world-class-scientific-advisory-board.html): Leading immuno-oncology and autoimmune experts to help guide clinical development strategy and advance pipeline of novel antibody drugs CAMBRIDGE, Mass., SHANGHAI, and PARIS – October 28, 2019 – HiFiBiO Therapeutics, a pioneer in innovative biotherapeutics with a unique single-cell analytics platform for extensive immune profiling, today announced the formation of a Scientific Advisory Board (SAB) […] (602 words, Oct 28, 2019)
- [HiFiBiO Therapeutics Closes $67 Million Series C Financing to Build on Recent Success and Advance Pipeline of Novel Antibody Drugs for Cancer and Autoimmune Disorders - HiFiBio Therapeutics](/content/hifibio-therapeutics-closes-67-million-series-c-financing-to-build-on-recent-success-and-advance-pipeline-of-novel-antibody-drugs-for-cancer-and-autoimmune-disorders.html): Latest funding led by IDG Capital with participation from Sequoia Capital China, Delian Capital, Hanne Capital, VI Ventures, Legend Star Capital, LYFE Capital, and Kite, a Gilead Company  CAMBRIDGE, Mass., SHANGHAI, and PARIS, – August 28, 2019 – HiFiBiO Therapeutics, a pioneer in innovative biotherapeutics with a unique single-cell analytics platform for extensive immune profiling, […] (684 words, Aug 28, 2019)
- [HiFiBiO Therapeutics and Leading Academic Institutions Demonstrate Breakthrough Single-Cell Approach for Novel Biomarker Discovery to Combat Cancer - HiFiBio Therapeutics](/content/hifibio-therapeutics-and-leading-academic-institutions-demonstrate-breakthrough-single-cell-approach-for-novel-biomarker-discovery-to-combat-cancer.html): The Nature Genetics publication describes a novel high-throughput single-cell ChIP-seq approach to studying heterogeneity of chromatin states within complex biological systems. Our proprietary single-cell CelliGO platform and unique DIS capabilities were used to probe why certain disease cells are resistant to available therapeutics. (586 words, Jun 3, 2019)
- [High-Throughput Single-Cell ChIP-Seq Identifies Heterogeneity of Chromatin States in Breast Cancer - HiFiBio Therapeutics](/content/high-throughput-single-cell-chip-seq-identifies-heterogeneity-of-chromatin-states-in-breast-cancer.html) (11 words, May 31, 2019)
- [Victa Biotherapeutics Appoints Donald W. Kufe to Board of Directors - HiFiBio Therapeutics](/content/victa-biotherapeutics-appoints-donald-w-kufe-to-board-of-directors.html): Distinguished Dana-Farber Cancer Institute Physician and Harvard Medical School Professor joins new open-innovation, immuno-oncology joint venture between HiFiBiO Therapeutics and Vikas P. Sukhatme CAMBRIDGE, Mass. – February 12, 2019 – HiFiBiO Therapeutics, a world leader in the discovery and development of therapeutic antibodies enabled by unique single-cell profiling and full immune repertoire screening, today announced Donald W. […] (702 words, Feb 13, 2019)
- [HiFiBiO Therapeutics and Vikas Sukhatme Join Forces to Discover and Develop Novel Antibody Treatments for Cancer - HiFiBio Therapeutics](/content/hifibio-therapeutics-and-vikas-sukhatme-join-forces-to-discover-and-develop-novel-antibody-treatments-for-cancer.html): Victa Biotherapeutics is a new open-innovation joint venture designed to further validate Dr. Sukhatme’s pioneering immuno-oncology research in precision medicine applications   CAMBRIDGE, Mass. – Dec. 10, 2018 – HiFiBiO Therapeutics, a world leader in the discovery of therapeutic antibodies through single-cell screening and analysis, today announced the formation of Victa Biotherapeutics, a joint venture […] (479 words, Dec 10, 2018)
- [HiFiBiO Therapeutics Acquires H-Immune Therapeutics - HiFiBio Therapeutics](/content/hifibio-theraputics-aquires-h-immune-therapeutics/index.html): Companies join forces to target different T cell subsets and combat cancer CAMBRIDGE, Mass., PARIS and SHANGHAI – Oct. 15, 2018 – HiFiBiO Therapeutics, a world leader in the discovery of therapeutic antibodies through single-cell screening and analysis, announced today the acquisition of H-Immune Therapeutics, an early-stage biotechnology company engaged in the discovery and development […] (519 words, Oct 15, 2018)
- [Research Collaboration to Develop Technology for the Treatment of Cancer - HiFiBio Therapeutics](/content/kite-and-hifibio-therapeutics-announce-a-research-collaboration-to-develop-technology-for-the-potential-discovery-of-neoantigen-reactive-t-cell-receptors-tcrs-for-the-treatment-of-cancer.html): Santa Monica, Calif. and Hong Kong, October 2, 2018 – Kite, a Gilead Company (Nasdaq: GILD), and HiFiBiO Therapeutics, a biotechnology company focused on the discovery of therapeutic antibodies through single B cell screening and analysis, announced the companies have entered into a research collaboration and license agreement to develop technology supporting the discovery of […] (694 words, Oct 2, 2018)
- [HiFiBiO Therapeutics Signs Multi-Target Antibody Discovery Agreement with Takeda - HiFiBio Therapeutics](/content/hifibio-therapeutics-signs-multi-target-antibody-discovery-agreement-with-takeda.html): Global pharmaceutical leader selects innovative single-B-cell technology to generate breakthrough therapies CAMBRIDGE, Mass., SHANGHAI, China, and PARIS, France – July 30, 2018 – HiFiBiO Therapeutics, a world leader in the discovery of therapeutic antibodies through single-B-cell screening and analysis, today announced a multi-target agreement with Takeda Pharmaceutical Company Limited (Takeda) to enable the discovery of […] (328 words, Jul 30, 2018)
- [HiFiBiO Therapeutics Secures $37.5 Million Series B Financing to Accelerate Pipeline of Novel Antibody Drugs to Treat Cancer and Autoimmune Disorders - HiFiBio Therapeutics](/content/hifibio-therapeutics-secures-37-5-million-series-b-financing-to-accelerate-pipeline-of-novel-antibody-drugs-to-treat-cancer-and-autoimmune-disorders.html): Multinational biotherapeutics company announces a new leadership team, expands its global footprint and advances an innovative portfolio of immune modulators for unmet medical needs CAMBRIDGE, Mass., HANGZHOU, China, and PARIS – May 16, 2018 – HiFiBiO Therapeutics, a world leader in the discovery of therapeutic antibodies through single-B-cell screening and analysis, today announced the completion […] (996 words, May 16, 2018)
- [HiFiBiO and collaborators publish single-cell microfluidics work in Nature Biotechnology - HiFiBio Therapeutics](/content/hifibio-and-collaborators-publish-single-cell-microfluidics-work-in-nature-biotechnology.html): CAMBRIDGE, MA, AND PARIS, FRANCE, 12 October, 2017 – HiFiBiO and collaborators describe the application of droplet microfluidics to characterize immune responses at the single-cell level in work published in Nature Biotechnology. Eyer et al‘s paper, “Single-cell deep phenotyping of IgG-secreting cells for high-resolution immune monitoring” describes DropMap, “a powerful and elegant technology for the phenotypic analysis of antibody-secreting cells […] (241 words, Oct 12, 2017)
- [Shared Insights About Guiding Principles of Open Collaboration in Drug Discovery Today From HiFiBiO CEO Liang Schweizer - HiFiBio Therapeutics](/content/drug-discovery-today/index.html): Guiding principles of value creation through collaborative innovation in pharmaceutical research HiFiBiO CEO Liang Schweizer and COO Jeff He outline the importance of breaking down common barriers in collaborations, propose four guiding principles for such co-operation and offer a framework to reach value inflection points quicker. (155 words, Oct 9, 2017)
- [Guiding Principles of Value creation Through Collaborative Innovation in Pharmaceutical Research - HiFiBio Therapeutics](/content/guiding-principles-of-value-creation-through-collaborative-innovation-in-pharmaceutical-research.html) (11 words, Oct 8, 2017)
- [Single-Cell Deep Phenotyping of IgG-Secreting Cells for High-Resolution Immune Monitoring - HiFiBio Therapeutics](/content/single-cell-deep-phenotyping-of-igg-secreting-cells-for-high-resolution-immune-monitoring.html) (10 words, Sep 11, 2017)
- [Single-Cell Deep Phenotyping of lgG-Secreting Cells for High-Resolution Immune Monitoring - HiFiBio Therapeutics](/content/nature-biotechnology/index.html): The Nature Biotechnology manuscript details DropMap, “a powerful and elegant technology for the phenotypic analysis of antibody-secreting cells (ASCs) at the single-cell level with unprecedented throughput and resolution.” This droplet microfluidics approach was developed with collaborators from ESPCI and Institut Pasteur. (91 words, Sep 11, 2017)
- [HiFiBiO at PEPTalk - HiFiBio Therapeutics](/content/peptalk/index.html): CAMBRIDGE, MA, AND PARIS, FRANCE, January 9, 2017 – HiFiBiO SAS today announced that the latest results from their CelliGO™ platform will be presented by Dr. Roshan Kumar, Group Leader in Cambridge, as part of the ‘Emerging Technologies for Antibody Discovery’ track at PEPTalk 2017 in San Diego. The presentations will feature the latest achievements […] (179 words, Jan 9, 2017)
- [Antibody Discovery by Deep Mining of Immune Repertoires: A Demonstration of the HiFiBiO CelliGO™ Platform Versatility and Robustness with Tetanus Toxoid Antigen as a Case Study - HiFiBio Therapeutics](/content/antibody-discovery-by-deep-mining-of-immune-repertoires-a-demonstration-of-the-hifibio-celligo-platform-versatility-and-robustness-with-tetanus-toxoid-antigen-as-a-case-study.html) (26 words, Nov 13, 2016)
- [HiFiBiO SAS to present advances in functional therapeutic antibody discovery at The European Antibody Congress on Tuesday, November 15, 2016 - HiFiBio Therapeutics](/content/hifibio-sas-to-present-advances-in-functional-therapeutic-antibody-discovery-at-the-european-antibody-congress-on-tuesday-november-15-2016.html): CAMBRIDGE, MA, AND PARIS, FRANCE, November 11, 2016 – HiFiBiO SAS today announced that the latest results from their CelliGO™ platform will be presented by Senior Scientist and Project Leader Dr. Annabelle Gerard as part of the 2016 European Antibody Conference taking place in Basel, Switzerland. The presentations will feature the latest achievements in deep mining […] (111 words, Nov 11, 2016)
- [Antibody Discovery by Deep Mining of Immune Repertoires - HiFiBio Therapeutics](/content/antibody-discovery-by-deep-mining-of-immune-repertoires.html): Antibody Discovery by Deep Mining of Immune Repertoires: A demonstration of the HiFiBiO CelliGO™ Platform versatility and robustness with Tetanus Toxoid antigen as a case study (38 words, Nov 11, 2016)
- [HiFiBiO SAS to Present Advances in Functional Therapeutic Antibody Discovery with Two Talks at Human Antibodies and Hybridomas Conference to Be Held in Belfast, Northern Ireland, Wednesday, November 9, 2016 - HiFiBio Therapeutics](/content/hifibio-sas-to-present-advances-in-functional-therapeutic-antibody-discovery-with-two-talks-at-human-antibodies-and-hybridomas-conference-to-be-held-in-belfast-northern-ireland-wednesday-november-9.html): CAMBRIDGE, MA, AND PARIS, FRANCE, November 7, 2016 – HiFiBiO SAS today announced that the latest results from their CelliGO™ platform will be presented by Senior Scientists and Project Leaders, Dr Adam Woolfe and Dr. Marcel Reichen as part of the 2016 Human Antibodies and Hybridomas Conference. The presentations will feature the latest achievements in deep […] (144 words, Nov 7, 2016)
- [HiFiBiO receives recognition as one of Biocentury Innovations - HiFiBio Therapeutics](/content/hifibio-receives-recognition-as-one-of-biocentury-innovations.html): HiFiBiO receives recognition as one of Biocentury Innovations’ Emerging Companies in an article entitled “Mining for Functionality” published May 16th in Biocentury’s online magazine. Paris, France, May 29th, 2016 — HiFiBiO receives recognition as one of Biocentury Innovations’ Emerging Companies in an article entitled “Mining for Functionality” published May 16th. To see the Biocentury article […] (66 words, May 26, 2016)
- [HiFiBiO SAS announces participation in next generation antibody therapeutics session along with Adimab, F-Star and Innovative Targeting Solutions at BioInternational 2016 in San Francisco, USA - HiFiBio Therapeutics](/content/hifibio-sas-announces-participation-in-next-generation-antibody-therapeutics-session-along-with-adimab-f-star-and-innovative-targeting-solutions-at-biointernational-2016-in-san-francisco-usa-2.html): Paris, France and Cambridge, MA –May 16th, 2016–In an interactive session at BioInternational 2016, HiFiBiO, Adimab, F-Star and Innovative Targeting Solutions will join together to present next-generation therapeutic antibody technologies designed to help deliver the next wave of antibody therapeutics to the pipeline. Session Title: Tackling Tough Targets with a New Wave of Antibody Technologies […] (222 words, May 16, 2016)
- [HiFiBiO is Recognized as an “Innovative Start-up Company” by French President Francois Hollande at the Inauguration of the Institute Pierre-Gilles de Gennes - HiFiBio Therapeutics](/content/hifibio-is-recognized-as-an-innovative-start-up-company-by-french-president-francois-hollande-at-the-inauguration-of-the-institute-pierre-gilles-de-gennes.html): Paris, France. In the inauguration of the new microfluidics center the Institut Pierre Gilles de Gennes (IPGG), French President François Hollande recognized HiFiBiO SAS, a start-up company from Ecole Superieure de Physique and Chimie Industrielles de la ville de Paris (ESPCI), for its innovative application of single cell microdroplet technology for antibody discovery and development. […] (81 words, Mar 23, 2016)
- [HiFiBiO SAS to Report Results from the First Fully Integrated, Single-Cell Antibody Discovery Platform at IBC Antibody and Engineering Therapeutics 2015 Conference - HiFiBio Therapeutics](/content/hifibio-sas-to-report-results-from-the-first-fully-integrated-single-cell-antibody-discovery-platform-at-ibc-antibody-and-engineering-therapeutics-2015-conference.html): Screening entire immune repertoires generates diverse panels of therapeutic antibody leads November 23, 2015 10:00 AM Eastern Standard Time CAMBRIDGE, Mass. & PARIS–(BUSINESS WIRE)–HiFiBiO SAS today announced that the latest results from their CelliGOTM platform will be presented by Chief Scientific Officer, Dr. Allan Jensen, Dec. 7-10 San Diego, California. The presentation, will be on Tuesday, Dec. 8 at 13:45 […] (177 words, Nov 23, 2015)
- [HiFiBiO’s next generation antibody discovery platform to be presented by Pfizer Inc. at PEGS Europe 2015 - HiFiBio Therapeutics](/content/hifibios-next-generation-antibody-discovery-platform-to-be-presented-by-pfizer-inc-at-pegs-europe-2015.html): PARIS, FRANCE, October 27, 2015 – HiFiBiO SAS announced today that the company’s next generation antibody discovery platform will be presented at the Seventh Annual PEGS Europe 2015 Protein and Antibody Engineering Summit, Nov. 2-6 in Lisbon, Portugal. The presentation, by William S. Somers, Ph.D., Vice President, Global Biotherapeutic Technologies at Pfizer Inc., will be on Tuesday, Nov 3 at […] (144 words, Oct 27, 2015)
- [HiFiBiO SAS Achieves Milestone in Antibody Research Collaboration with Pfizer Inc. - HiFiBio Therapeutics](/content/hifibio-sas-achieves-milestone-in-antibody-research-collaboration-with-pfizer-inc.html): CAMBRIDGE, MA AND PARIS, FRANCE, August 13, 2015, 2015 – HiFiBiO SAS announced today the company has achieved a milestone in its research collaboration with Pfizer Inc., triggering a milestone payment to HiFiBiO. The focus of the collaboration, originally signed in 2014, is the development and validation of HiFiBiO’s proprietary, high throughput antibody discovery platform for deep […] (465 words, Aug 13, 2015)
- [HiFiBiO to present platform at next-generation antibodies conference - HiFiBio Therapeutics](/content/hifibio-to-present-platform-at-next-generation-antibodies-conference.html): Paris, France, 12 June 2015—HiFiBiO will present its novel, integrated platform for the discovery of differentiated therapeutic antibodies at the Next Generation Antibodies and Protein Analysis Conference: Tools and Technologies, on 15 June 2015, in Ghent, Belgium. In a presentation, “Deep Mining of Immune Repertoires”, HiFiBiO’s Chief Scientific Officer, Allan Jensen, PhD, will describe the company’s […] (128 words, Jun 12, 2015)
- [HiFiBiO partners with Johnson & Johnson Innovation - HiFiBio Therapeutics](/content/hifibio-partners-with-johnson-johnson-innovation/index.html): Exploring New Antibody Discovery Platforms – While current antibody discovery technologies, such as hybridomas, are highly reliable, they are also inefficient in terms of percentage of antigen-specific B cells identified during screening. HiFiBiO and Janssen Biotech, Inc. are collaborating to evaluate the company’s single cell technology for genetically characterizing individual cells as a potential new […] (90 words, Jun 12, 2015)

## About Pages

- [Contact - HiFiBio Therapeutics](/content/about/contact/index.html) (25 words)
- [About - HiFiBio Therapeutics](/content/about/index.html) (13 words)

## Resources

- [Full Page Index](/index.html): Browse all cached pages with rich metadata
- [About This Cache](/content/about.html): Methodology, technical details, and usage guidelines
- [XML Sitemap](/sitemap.xml): Machine-readable sitemap for crawler discovery
- [Robots.txt](/robots.txt): Crawler directives